This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.
The goal of this activity is to increase clinicians' understanding of the immune system and avenues of immune modulation beyond the currently available checkpoint inhibitors.
Have increased knowledge regarding the unmet medical need in patients with cancer whose disease does not respond to or becomes resistant to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and/or cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition
Have increased knowledge regarding the avenues of immune modulation beyond PD-1/PD-L1 and CTLA-4 inhibition to improve immune recognition of cancer cells and tumors
Have increased knowledge regarding the mid-to-late stage clinical trial data on the use of novel strategies to modulate the immune system to treat patients with cancer
Approximate Time to Complete: 30 minutes
Credit Available: December 23rd, 2020 - December 23rd, 2021
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC:
Certificate in Cancer Immunotherapy